scholarly journals Use Of External Data To Guide Long-Term Survival Extrapolations Of Trial Data For Chronic Lymphocytic Leukemia

2014 ◽  
Vol 17 (7) ◽  
pp. A563 ◽  
Author(s):  
E. Hawe ◽  
I. Pearson ◽  
S. Wolowacz ◽  
A. Haiderali
Haematologica ◽  
2017 ◽  
Vol 103 (4) ◽  
pp. e158-e161 ◽  
Author(s):  
Panagiotis Baliakas ◽  
Mattias Mattsson ◽  
Anastasia Hadzidimitriou ◽  
Eva Minga ◽  
Andreas Agathangelidis ◽  
...  

2021 ◽  
Vol 10 (2) ◽  
pp. 139
Author(s):  
ShokhanMohammad Mustafa ◽  
AhmedKhudair Yassin ◽  
NawsherwanS Mohammed ◽  
RawandP Shamoon ◽  
MarwaN Karam ◽  
...  

Blood ◽  
2008 ◽  
Vol 111 (10) ◽  
pp. 4916-4921 ◽  
Author(s):  
Hermann Brenner ◽  
Adam Gondos ◽  
Dianne Pulte

Abstract Although chronic lymphocytic leukemia (CLL) has remained incurable with standard treatments, newer therapeutic approaches, such as chemoimmunotherapy or stem cell transplantation, bear the potential for prolonged survival. We estimated trends in age-specific 5- and 10-year absolute and relative survival of CLL patients in the United States between 1980-1984 and 2000-2004 from the 1973 to 2004 database of the Surveillance, Epidemiology, and End Results Program. Period analysis was used to disclose recent developments with minimum delay. Overall, 5- and 10-year absolute survival from diagnosis increased from 54.2% to 60.2% (+6 percentage points; P < .0001) and from 27.8% to 34.8% (+7 percentage points; P < .0001), respectively. Despite a strong age gradient in prognosis, increases in 5-year absolute and relative survival over time were rather homogeneous across age groups. In contrast, increases in 10-year absolute and relative survival close to or well above 10% units were observed for all patients younger than 80 years of age at diagnosis compared with no increase at all for older patients. Long-term survival expectations of patients with CLL have substantially improved over the past 2 decades except for patients 80 years of age or older at the time of diagnosis. Future studies are needed to confirm and expand our findings.


Cancer ◽  
1981 ◽  
Vol 48 (11) ◽  
pp. 2364-2367 ◽  
Author(s):  
Franco Mandelli ◽  
Sergio Amadori ◽  
Adriana Ceci ◽  
Carlo Guazzelli ◽  
Enrico Madon ◽  
...  

1976 ◽  
Vol 2 (3) ◽  
pp. 333-351 ◽  
Author(s):  
Jacqueline Whang-Peng ◽  
Turid Knutsen ◽  
John Ziegler ◽  
Brigid Leventhal

2022 ◽  
Vol 8 ◽  
Author(s):  
Ga-Won Lee ◽  
Min-Hee Kang ◽  
Jin-Ha Jeon ◽  
Doo-Won Song ◽  
Woong-Bin Ro ◽  
...  

A 7-year-old castrated male Poodle dog presented with chronic progressive lymphocytosis. Hematologic and peripheral blood smear findings included remarkable lymphocytosis with well-differentiated small lymphocytes. Cytology of bone marrow aspirate showed hypercellular integrity with infiltration of small mature lymphocytes, accounting for 45% of all nucleated cells. Flow cytometry of blood and marrow samples revealed neoplastic lymphocytes predominantly expressing the CD21 molecule. B-cell chronic lymphocytic leukemia (CLL) was diagnosed on an immunophenotypic analysis. Administrations of prednisolone and chlorambucil were initiated and the response was unremarkable. Therefore, additional treatment with imatinib was provided, which resolved the hematologic abnormalities associated with CLL. Flow cytometry after ~1 year of treatment showed normalization of the count of lymphocytes positive for CD21 and resolved hematologic lymphocytosis. The dog was followed-up for 2 years, and there were no severe adverse effects. This case indicates that imatinib may be a good option as an adjunctive therapy with prednisolone and chlorambucil treatment for CLL in dogs without treatment response.


2000 ◽  
Vol 111 (1) ◽  
pp. 363-370 ◽  
Author(s):  
Katsuto Takenaka ◽  
Mine Harada ◽  
Tomoaki Fujisaki ◽  
Koji Nagafuji ◽  
Shinichi Mizuno ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A747-A748
Author(s):  
S DRESNER ◽  
A IMMMANUEL ◽  
P LAMB ◽  
S GRIFFIN

Sign in / Sign up

Export Citation Format

Share Document